Acute Rheumatic Fever

1. Clinical Overview

Summary

Acute rheumatic fever (ARF) is an inflammatory disease that develops as a delayed sequela of Group A streptococcal (GAS) pharyngitis, affecting the heart, joints, central nervous system, and skin. The condition results from an autoimmune response triggered by molecular mimicry between streptococcal antigens and human tissues. ARF predominantly affects children and young adults (5-15 years) and remains a leading cause of acquired heart disease in developing countries, with an estimated global incidence of 8-51 per 100,000 population. [1] The diagnosis relies on the revised 2015 Jones criteria, which differentiate between low-risk and moderate-to-high-risk populations, incorporating echocardiographic findings of subclinical carditis as a major criterion. [2] Management includes eradication of GAS infection with penicillin, anti-inflammatory therapy (aspirin for arthritis, corticosteroids for severe carditis), and long-term secondary prophylaxis with benzathine penicillin G to prevent recurrence. [3] While most acute manifestations resolve, rheumatic carditis can cause permanent valvular heart disease (rheumatic heart disease), making prevention through appropriate antibiotic prophylaxis essential for reducing global disease burden.

Key Facts

• Definition: Post-infectious inflammatory syndrome following Group A streptococcal pharyngitis, affecting heart, joints, brain, and skin
• Global Incidence: 8-51 per 100,000 in developing countries; 1-3 per 100,000 in developed countries [1]
• Mortality: less than 1% in acute phase unless complicated by severe carditis; long-term mortality relates to development of rheumatic heart disease
• Peak age: Children and young adults (5-15 years)
• Latent period: Typically 2-4 weeks post-streptococcal pharyngitis
• Critical feature: Only pharyngitis (not skin infection) triggers ARF
• Key investigation: 2015 Revised Jones criteria, evidence of preceding GAS infection (ASO/anti-DNase B), echocardiography for carditis [2]
• First-line treatment: Penicillin (eradicate GAS), anti-inflammatories (aspirin or corticosteroids), long-term prophylaxis (benzathine penicillin G) [3]

Clinical Pearls

"2-4 week latent period" — ARF typically manifests 2-4 weeks after an episode of GAS pharyngitis. This latent period distinguishes ARF from acute suppurative complications of streptococcal infection.

"Revised Jones Criteria 2015" — The 2015 AHA revision stratifies diagnostic criteria by population risk: moderate-to-high-risk populations have less stringent criteria, including monoarthritis/polyarthralgia as major criteria and subclinical carditis detected by echocardiography. [2]

"Carditis determines prognosis" — The presence and severity of carditis (affecting 50-70% of ARF patients) is the principal determinant of long-term outcomes, as it may progress to chronic rheumatic heart disease with permanent valvular damage. [4]

"Benzathine penicillin adherence critical" — Secondary prophylaxis with intramuscular benzathine penicillin G every 3-4 weeks reduces recurrence risk by > 90% and is the cornerstone of rheumatic heart disease prevention. [5] Adherence remains challenging due to injection pain and access barriers.

"Chorea may present late" — Sydenham chorea can appear months after the initial streptococcal infection and may be the sole manifestation of ARF, often occurring when other criteria have resolved. [6]

Why This Matters Clinically

ARF represents a preventable cause of acquired heart disease, particularly in resource-limited settings where it accounts for significant cardiovascular morbidity and mortality in young people. Early recognition using the 2015 revised Jones criteria, appropriate acute management with anti-inflammatory therapy, and rigorous adherence to long-term penicillin prophylaxis can prevent progression to chronic rheumatic heart disease. Understanding population-specific risk stratification and the role of echocardiography in detecting subclinical carditis is essential for contemporary ARF diagnosis and management.

---

2. Epidemiology

Incidence & Prevalence

• Global burden: 470,000 new ARF cases annually worldwide, with 33.4 million people living with rheumatic heart disease [7]
• Developed countries: 1-3 per 100,000 population (significant decline since 1950s)
• Developing countries: 8-51 per 100,000 population [1]
• High-risk regions: Sub-Saharan Africa, South Asia, Oceania (Indigenous populations), parts of Latin America
• Trend: Declining in high-income countries due to improved living conditions, access to antibiotics; persistent high rates in low- and middle-income countries
• Peak age: 5-15 years (rare before age 3 or after age 30)

Demographics

Risk Factors

Non-Modifiable:

• Age 5-15 years (highest susceptibility to initial attack)
• Genetic susceptibility (HLA-DR7, HLA-DRw53 associations reported)
• Previous ARF history (50-fold increased recurrence risk) [8]
• Geographic location in endemic region
• Ethnicity (Indigenous, South Asian populations)

Modifiable:

Attack Rate Following GAS Pharyngitis

• Epidemic settings: Up to 3% of untreated pharyngitis cases [2]
• Endemic settings: 0.3-3% depending on virulence of circulating GAS strains
• Recurrence rate without prophylaxis: Up to 50% within 5 years
• Recurrence rate with adequate prophylaxis: less than 5% [5]

---

3. Pathophysiology

The Molecular Mimicry Mechanism

Step 1: Group A Streptococcal Pharyngitis

• Infection: β-hemolytic Group A streptococcus (Streptococcus pyogenes) colonizes pharynx
• Key antigens: M protein (major virulence factor), streptococcal cell wall, streptococcal carbohydrate
• Immune activation: Innate and adaptive immune responses activated
• Note: Only pharyngeal infection (not skin/pyoderma) triggers ARF, likely due to differences in streptococcal strain types and immune response patterns

Step 2: Molecular Mimicry and Autoimmunity

• Structural homology: Streptococcal M protein shares epitopes with human cardiac myosin, tropomyosin, laminin, and brain tissue components [9]
• Cross-reactive antibodies: Anti-streptococcal antibodies recognize self-antigens on heart valves, myocardium, basal ganglia, synovium
• T-cell activation: CD4+ T cells recognizing streptococcal antigens cross-react with valve and brain tissue
• Cytokine cascade: IL-1, IL-6, TNF-α production drives inflammatory response
• Result: Autoimmune attack on multiple organ systems 2-4 weeks post-infection

Step 3: Tissue-Specific Inflammation

Step 4: Resolution and Chronic Sequelae

• Acute phase: 6-12 weeks with appropriate anti-inflammatory treatment
• Valve healing: Most inflammation resolves, but repeated attacks cause progressive fibrosis and calcification
• Chronic RHD: Develops in 30-50% of patients with carditis, manifesting as stenosis and/or regurgitation [4]

Aschoff Bodies (Pathognomonic Finding)

• Definition: Granulomatous lesions in myocardium consisting of fibrinoid necrosis surrounded by lymphocytes, plasma cells, and large histiocytes (Anitschkow cells)
• Significance: Pathognomonic for rheumatic carditis (though rarely biopsied clinically)
• Evolution: Acute → chronic fibrous scar over months to years

Why Only Pharyngitis Triggers ARF

• Strain specificity: "Rheumatogenic" GAS strains (certain M protein types: M1, M3, M5, M6, M18, M24) more common in pharyngeal infections
• Mucosal immunity: Pharyngeal mucosa-associated lymphoid tissue produces different immune response than skin
• Antibody patterns: Pharyngeal infections elicit higher anti-M protein antibody titers

---

4. Clinical Presentation

Revised Jones Criteria (2015) - Diagnostic Framework [2]

The American Heart Association revised the Jones criteria in 2015 to improve diagnostic sensitivity, particularly in moderate-to-high-risk populations. Diagnosis requires: Evidence of preceding GAS infection PLUS 2 major criteria OR 1 major + 2 minor criteria.

Population Risk Stratification:

• Low-risk: ARF incidence less than 2 per 100,000 school-aged children per year OR RHD prevalence ≤1 per 1,000 population
• Moderate-to-high-risk: ARF incidence ≥2 per 100,000 per year OR RHD prevalence > 1 per 1,000 population

Major Criteria

Minor Criteria

Key Changes in 2015 Revision:

1. Population-specific criteria (acknowledges different presentation patterns in endemic regions)
2. Inclusion of monoarthritis and monoarthralgia in moderate-high-risk populations
3. Subclinical carditis (echo-detected) elevated to major criterion
4. Lower inflammatory marker thresholds for moderate-high-risk populations

Evidence of Preceding GAS Infection (Required)

Interpretation Notes:

• Single elevated titer suggests recent infection; rising titer (> 2 dilutions) more specific
• 20% of ARF patients may have negative ASO; anti-DNase B increases combined sensitivity to > 95% [10]
• Antibody titers may be low/absent in pure chorea (due to delayed presentation)

Clinical Manifestations - Detailed Description

1. Carditis (50-70% of cases) [4]

Clinical Carditis:

• Symptoms: Dyspnea, orthopnea, chest pain (pericarditis), palpitations
• Signs:
  • Tachycardia disproportionate to fever
  • New or changed murmur (mitral regurgitation most common, then aortic regurgitation)
  • Carey Coombs murmur (mid-diastolic rumble from mitral valvulitis)
  • S3 gallop, cardiomegaly
  • Pericardial friction rub (10-15% of carditis cases)
  • Signs of heart failure (severe cases)

Subclinical Carditis (Echo-Detected):

• Definition: Echocardiographic evidence of valvulitis without clinical signs [2]
• Findings:
  • "Mitral regurgitation (MR): pathological if jet length ≥2 cm, occupies ≥2 cm² of LA, pan-systolic jet in at least 1 view"
  • "Aortic regurgitation (AR): pathological if jet length ≥1 cm in at least 2 views"
  • "Morphological features: valve thickening, restricted leaflet motion, elongated chordae"
• Significance: WHO classification suggests subclinical carditis has similar progression risk to clinical carditis [11]
• Prevalence: Adds 10-20% to carditis detection rate

Valve Involvement:

• Mitral valve only: 50-60%
• Mitral + aortic valves: 20%
• Aortic valve only: Rare (less than 5%)
• Tricuspid/pulmonary: Extremely rare

2. Arthritis (35-66% of cases)

Classic Polyarthritis:

• Pattern: Migratory, asymmetric, affects large joints sequentially
• Joints: Knees > ankles > wrists > elbows (rarely small joints)
• Characteristics:
  • Each joint inflamed 2-7 days before migrating
  • Exquisitely painful, swollen, warm, red
  • Dramatic response to aspirin/NSAIDs (within 24-48 hours)
  • Complete resolution without deformity (unlike other arthritides)
• Duration: 2-4 weeks total without treatment; less than 1 week with aspirin

Monoarthritis/Monoarthralgia (Moderate-High-Risk Populations):

• Recognized in 2015 Jones revision as major/minor criterion respectively in endemic settings
• Reflects clinical reality in populations with high background ARF rates

Additive vs Migratory:

• True migratory pattern (inflammation resolves in one joint before appearing in next): classic ARF
• Additive pattern (multiple joints simultaneously): consider alternative diagnosis

3. Sydenham Chorea (10-30% of cases) [6]

Clinical Features:

• Onset: Insidious, often months after pharyngitis (mean 6-7 months, up to 9 months)
• Movement disorder:
  • Involuntary, purposeless, dance-like movements
  • Exacerbated by stress, disappear during sleep
  • Facial grimacing, tongue protrusion, "milkmaid's grip"
  • Gait abnormality, inability to keep tongue protruded
• Associated features:
  • Hypotonia, motor impersistence
  • Emotional lability, behavioral changes, OCD-like symptoms [12]
  • Dysarthria, dysphagia (if severe)
• Pattern: May be unilateral (hemichorea) in 20-30%
• Duration: Typically 3-6 months (range: weeks to > 2 years)

Diagnostic Challenges:

• Often occurs in isolation without other Jones criteria
• Streptococcal serology may be negative due to time lag
• May be misdiagnosed as tic disorder, ADHD, or psychiatric illness
• Recent consensus guidelines emphasize need for formal assessment tools and immunotherapy consideration [6]

Management Specifics:

• Antiphietics only if movements significantly impair function
• Dopamine blockers (haloperidol 0.5-2mg daily, risk of extrapyramidal side effects) or valproate [13]
• Corticosteroids and IVIG considered in moderate-severe cases [6]
• Long-term penicillin prophylaxis essential
• Avoid stimulants (worsen chorea)

4. Erythema Marginatum (less than 6% of cases)

Characteristics:

• Appearance: Pink/red, non-pruritic, serpiginous (snake-like) rash with clear center
• Distribution: Trunk and proximal extremities; spares face
• Pattern: Expands centrifugally, individual lesions ephemeral (change within hours)
• Provocation: May become more apparent with warmth/bathing
• Timing: Early in disease course, may persist or recur for months
• Significance: Highly specific when present, but rarely seen

5. Subcutaneous Nodules (less than 10% of cases)

Characteristics:

• Appearance: Firm, painless, pea-sized (0.5-2 cm) nodules
• Location: Over bony prominences/extensor surfaces (elbows, knees, occiput, spinous processes)
• Pattern: Usually multiple (2-20 nodules)
• Timing: Late manifestation (2-3 weeks into illness)
• Duration: Persist weeks to months
• Associated finding: Almost always occur with carditis, often severe
• Significance: Highly specific but rare in contemporary series

Symptoms: The Patient's Story

Typical Presentation:

1. Recent pharyngitis: Sore throat 2-4 weeks prior (may have been untreated or partially treated)
2. Acute onset (over days):
   • High fever (38.5-40°C)
   • Severe joint pain and swelling (polyarthritis)
   • May describe joints "too painful to move"
3. Subsequent features (within first week):
   • Breathlessness, fatigue (if carditis present)
   • Chest pain (if pericarditis)
   • Rash (rarely reported spontaneously)
4. Later presentation (weeks to months):
   • Involuntary movements, behavioral changes (Sydenham chorea)

Atypical Presentations:

• Pure chorea without other manifestations (10-20% of chorea cases)
• Isolated carditis detected on routine examination
• Recurrent attacks may have milder features due to partial immunity

Red Flags

[!CAUTION] Red Flags — Immediate Escalation Required:

• Heart failure (dyspnea, orthopnea, peripheral edema, hepatomegaly) — indicates severe carditis, requires urgent cardiology assessment and ICU consideration
• Pericardial effusion (large effusions may cause tamponade) — echocardiography essential
• Severe chorea with dysphagia or self-injury — aspiration risk, may require immunotherapy [6]
• Recurrent ARF despite prophylaxis — check adherence, consider resistant GAS, may indicate failure of prophylaxis regimen
• Pancarditis (all three layers involved) — associated with worst prognosis

---

5. Investigations

Diagnostic Approach - Systematic

Step 1: Establish Evidence of Preceding GAS Infection

Key Point: 20% of ARF cases have normal ASO; combined ASO + anti-DNase B testing achieves 95% sensitivity for recent GAS infection. [10]

Step 2: Apply Jones Criteria Based on Population Risk

See Section 4 for detailed 2015 revised Jones criteria. Remember to stratify by local ARF incidence/RHD prevalence.

Step 3: Assess for Carditis (All Patients)

Laboratory Tests

Inflammatory Marker Kinetics:

• CRP: Rises within 6-12 hours, peaks 48 hours, normalizes within 1-2 weeks of treatment
• ESR: Rises more slowly, peaks at 1-2 weeks, may remain elevated 4-6 weeks despite treatment
• Monitor trend: Lack of improvement may indicate inadequate treatment or complication

Electrocardiography

Common Findings:

• PR interval prolongation (1st-degree AV block): 25-40% of cases, minor criterion [2]
  • Age/heart rate-adjusted PR interval > 0.20 sec (adults), > 0.18 sec (children less than 12y)
  • May progress to 2nd-degree block in severe carditis
  • Resolves with treatment, no long-term sequelae
• Tachycardia: Disproportionate to fever
• ST-T wave changes: Non-specific myocardial inflammation
• Low voltage: If pericardial effusion present
• Arrhythmias: Rare in acute phase; atrial fibrillation suggests chronic RHD

Diagnostic Value:

• PR prolongation alone not diagnostic (occurs in many conditions)
• Serial ECGs useful to monitor carditis severity and treatment response
• Holter monitoring if palpitations or suspected intermittent arrhythmia

Echocardiography (Essential in All Cases) [2,11]

Indications:

• Mandatory: All suspected ARF cases (detect subclinical carditis)
• Repeat: If initial negative but high clinical suspicion, 1-2 weeks later
• Follow-up: Serial echo at 1, 6, 12 months to assess valve progression

Protocol:

• Comprehensive 2D, color Doppler, and spectral Doppler
• Focus on mitral and aortic valves
• Assess for pericardial effusion, ventricular function

Findings - Acute Rheumatic Carditis:

Morphological (Valve Structure):

• Leaflet thickening (especially at coaptation points)
• Restricted leaflet motion
• Elongated or ruptured chordae tendineae
• Beading of leaflet tips
• Annular dilatation

Functional (Valve Hemodynamics):

Subclinical Carditis:

• Echo evidence of valvulitis without audible murmur [2]
• Prevalence: Adds 10-20% to clinical carditis detection
• Prognosis: WHO data suggest similar RHD progression risk to clinical carditis [11]

Other Findings:

• Pericardial effusion (typically small, less than 10 mm)
• LV dysfunction (if myocarditis severe)
• Chamber dilatation (if regurgitation significant)

Serial Echocardiography:

• Baseline → 1 month → 6 months → 12 months
• Purpose: Monitor valve changes, guide treatment duration, detect RHD development
• RHD definition: Persistent valve disease ≥6 months post-ARF [11]

Chest Radiography

Indications:

• Suspected heart failure
• Respiratory symptoms
• Baseline if carditis present

Findings:

• Cardiomegaly: Cardiothoracic ratio > 0.5 (if significant MR or heart failure)
• Pulmonary edema: Perihilar haze, Kerley B lines, pleural effusions (if LV failure)
• Pericardial effusion: "Water bottle" heart contour if large
• Normal CXR: Does not exclude carditis (echo more sensitive)

Advanced/Specialized Investigations

Cardiac MRI:

• Reserved for cases with unclear echo findings
• Can assess myocardial inflammation (T2 mapping, late gadolinium enhancement)
• Useful if considering alternate diagnoses (myocarditis, pericarditis)

Cardiac Catheterization:

• No role in acute ARF diagnosis
• Reserved for pre-operative assessment of chronic RHD

Endomyocardial Biopsy:

• Not routinely performed (Aschoff bodies pathognomonic but biopsy risky)
• May be considered if diagnostic uncertainty between ARF carditis vs viral myocarditis in resource-rich settings

---

6. Management

Management Algorithm - Evidence-Based Approach

        SUSPECTED ACUTE RHEUMATIC FEVER
    (Fever + major Jones criterion + preceding pharyngitis)
                    ↓
┌────────────────────────────────────────────────────┐
│         DIAGNOSTIC CONFIRMATION                     │
│  • Apply 2015 Revised Jones Criteria [2]            │
│  • Stratify by population risk (low vs mod-high)    │
│  • Evidence of GAS: ASO + anti-DNase B [10]         │
│  • Echocardiography: all cases (subclinical carditis)│
│  • Blood tests: FBC, ESR, CRP                       │
└────────────────────────────────────────────────────┘
                    ↓
┌────────────────────────────────────────────────────┐
│      IMMEDIATE MANAGEMENT (Day 1)                   │
│  1. Eradicate GAS Infection [3]                     │
│     → Benzathine penicillin G 1.2 MU IM × 1, OR     │
│     → Phenoxymethylpenicillin 500mg BD PO × 10d     │
│                                                     │
│  2. Anti-Inflammatory Therapy                       │
│     NO CARDITIS:                                    │
│     → Aspirin 100 mg/kg/day (max 4g/day) × 4-6w [14]│
│     → Taper over 2 weeks                            │
│                                                     │
│     MILD-MODERATE CARDITIS:                         │
│     → Prednisolone 1-2 mg/kg/day (max 60mg/day)    │
│     → Duration 2-4 weeks, taper over 2-3 weeks [14]│
│     → Overlap with aspirin during taper             │
│                                                     │
│     SEVERE CARDITIS/HEART FAILURE:                  │
│     → Methylprednisolone 10-30 mg/kg IV (max 1g)   │
│       × 3 days, then oral prednisolone [15]        │
│     → Consider pulse therapy protocol [15]          │
│                                                     │
│  3. Supportive Care                                 │
│     → Bed rest (strict if moderate-severe carditis) │
│     → Heart failure management (diuretics, ACEi)    │
│     → Chorea: haloperidol/valproate if severe [6,13]│
└────────────────────────────────────────────────────┘
                    ↓
┌────────────────────────────────────────────────────┐
│      SECONDARY PROPHYLAXIS (Day 7-14) [5]          │
│  • Initiate BEFORE discharge                        │
│                                                     │
│  REGIMEN (Preferred):                               │
│  → Benzathine penicillin G 1.2 MU IM q3-4 weeks    │
│                                                     │
│  ALTERNATIVE (if IM not feasible):                  │
│  → Phenoxymethylpenicillin 250mg BD PO daily       │
│                                                     │
│  PENICILLIN ALLERGIC:                               │
│  → Erythromycin 250mg BD PO daily, OR              │
│  → Sulfadiazine 0.5-1g OD PO daily                 │
│                                                     │
│  DURATION:                                          │
│  • No carditis: Until age 21 OR 5y post-ARF        │
│  • Carditis without RHD: Until age 21 OR 10y       │
│  • RHD (even mild): Until age 40 OR lifelong [16]  │
└────────────────────────────────────────────────────┘
                    ↓
┌────────────────────────────────────────────────────┐
│         MONITORING & FOLLOW-UP                      │
│  Week 1-2:   Clinical review, repeat inflammatory  │
│              markers (trend), echo if severe        │
│  Month 1:    Clinical exam, echo, ECG              │
│  Month 6:    Clinical exam, echo (assess RHD)      │
│  Month 12:   Clinical exam, echo (confirm RHD vs   │
│              resolution)                            │
│  Long-term:  6-12 monthly while on prophylaxis,    │
│              ensure adherence, dental prophylaxis   │
│              if RHD present                         │
└────────────────────────────────────────────────────┘

Acute/Emergency Management - The First 24-48 Hours

Immediate Actions (Do Simultaneously):

1. Confirm Diagnosis & Assess Severity

• Apply 2015 revised Jones criteria [2]
• Clinical examination: focus on carditis signs (murmur, tachycardia, heart failure), arthritis pattern
• Order investigations: FBC, ESR, CRP, ASO, anti-DNase B, throat culture, ECG, echo
• Risk stratify: Low vs moderate-high-risk population (affects criteria interpretation)

2. Eradicate GAS Infection [3]

3. Anti-Inflammatory Treatment [14]

No Carditis or Mild Arthritis:

Carditis Present (Moderate-Severe):

Severe Carditis/Heart Failure: [15]

Cochrane Review Evidence: [14]

• No RCT evidence that corticosteroids or aspirin prevent RHD development at 1 year
• Corticosteroids may hasten resolution of acute carditis symptoms
• Aspirin effective for arthritis control
• No difference in long-term cardiac outcomes between corticosteroids vs aspirin in most studies

4. Supportive Care

Bed Rest:

• Strict bed rest: Severe carditis or heart failure (2-4 weeks)
• Modified bed rest: Moderate carditis (1-2 weeks)
• Gradual mobilization: As symptoms improve, guided by clinical status

Heart Failure Management (if present):

Chorea Management (if severe): [6,13]

Recent Consensus (2025): International Delphi panel recommends corticosteroids as immunotherapy in moderate-severe Sydenham chorea, with IVIG or plasma exchange for inadequate responders. [6]

Secondary Prophylaxis - Cornerstone of RHD Prevention [5,16]

Evidence Base:

• Reduces ARF recurrence from ~50% to less than 5% over 5 years [5]
• Primary determinant of RHD prevention in patients with prior ARF
• Adherence challenges: injection pain, access barriers, healthcare system factors
• Cochrane review: benzathine penicillin G superior to oral penicillin for adherence [5]

Regimens:

Duration of Prophylaxis: [16]

WHO/AHA 2020 Update: [16]

• Emphasized lifelong prophylaxis consideration in all RHD patients
• Recognition of ongoing risk even decades post-ARF in endemic regions
• Individualize based on exposure risk, access to healthcare

Adherence Strategies:

• Pain management: Warm the injection to room temperature, use Z-track technique, apply ice pre-injection, post-injection analgesics
• Reminder systems: SMS reminders, patient registries, community health worker programs [17]
• Patient education: Emphasize prevention of valve damage, lifelong implications
• Access improvement: School-based programs, mobile clinics in endemic regions

Penicillin Allergy Management:

• True IgE-mediated allergy (anaphylaxis): use sulfadiazine or erythromycin
• Non-IgE reactions (rash): consider oral penicillin under supervision or alternatives
• Desensitization protocols: Rarely used, reserved for cases where alternatives ineffective

Disposition & Follow-Up

Admission Criteria:

• All confirmed ARF cases for initial assessment and treatment initiation (recommended)
• Mandatory admission: Carditis present, heart failure, severe chorea, diagnostic uncertainty

Discharge Criteria:

• Hemodynamically stable, no heart failure
• Established on appropriate anti-inflammatory therapy
• Secondary prophylaxis initiated or planned
• Echocardiography completed
• Follow-up arranged

Outpatient Management:

• Possible for mild cases (arthritis only) in resource-rich settings
• Requires reliable patient, close follow-up, access to investigations

Follow-Up Schedule:

Long-Term Considerations:

• Dental prophylaxis: If RHD with valve regurgitation/stenosis, follow infective endocarditis guidelines
• Pregnancy planning: Women with RHD require pre-conception counseling and high-risk obstetric care [18]
• Surgical planning: Progressive valve disease may require repair/replacement (timely referral to cardiac surgery)
• Transition to adult care: Coordinate at age 18-21 to maintain prophylaxis continuity
• Genetic counseling: Family members may have increased ARF susceptibility

---

7. Complications

Immediate (Days-Weeks)

Congestive Heart Failure:

• Most serious acute complication, indicates severe carditis
• Usually due to acute mitral and/or aortic regurgitation
• Requires intensive management: IV diuretics, oxygen, bed rest, consider methylprednisolone pulse [15]

Early (Weeks-Months)

1. Chorea Persistence or Late Onset (10-30% of ARF)

• May continue 3-6 months despite treatment
• Can appear months after acute episode (up to 9 months) [6]
• Requires symptomatic treatment if impairing function
• Relapse rate: ~20% (may occur years later)

2. Rebound Inflammation (5-15%)

• Occurs with too-rapid steroid/aspirin taper
• Presents with recurrent fever, arthritis, elevated inflammatory markers
• Management: Resume previous anti-inflammatory dose and taper more slowly

3. Steroid Side Effects

• Cushingoid features, weight gain, mood changes, hyperglycemia
• Monitor: blood pressure, glucose, behavior
• Usually resolve with tapering/cessation

Late (Months-Years)

1. Rheumatic Heart Disease (30-50% of patients with carditis) [4]

Definition:

• Persistent valvular dysfunction ≥6 months post-ARF [11]
• Characterized by fibrosis, calcification, and deformation of valve leaflets/apparatus

Prevalence:

• Develops in 30-50% of ARF patients with carditis
• Risk factors: Severe initial carditis, recurrent ARF, lack of prophylaxis

Valve Patterns:

Natural History Without Surgery:

• Progressive valve dysfunction over years to decades
• Heart failure, atrial fibrillation, thromboembolism (stroke risk 20-30× general population)
• Infective endocarditis (incidence 0.5-1% per year)
• Pregnancy complications in women (maternal mortality 1-5% if severe RHD) [18]

Management of Established RHD:

• Medical: Diuretics, ACEi/ARB, anticoagulation if AF or severe MS
• Interventional: Percutaneous balloon mitral valvuloplasty (if pure MS with favorable anatomy)
• Surgical: Valve repair (preferred) or replacement if severe symptomatic disease [16]

2. Recurrent ARF (Up to 50% without prophylaxis, less than 5% with prophylaxis) [5,8]

Risk Factors:

• Non-adherence to secondary prophylaxis (primary factor)
• Continued exposure to GAS (household crowding, endemic settings)
• Age less than 25 years
• Previous carditis (indicates susceptibility)

Consequences:

• Cumulative valve damage with each recurrence
• Accelerated progression to severe RHD
• Increased mortality risk

Prevention:

• Rigorous adherence to secondary prophylaxis [5]
• Early treatment of pharyngitis in family members
• Improved living conditions (reduced crowding)

3. Atrial Fibrillation (20-40% of severe RHD)

• Due to left atrial enlargement from mitral valve disease
• Increases stroke risk 5-fold (20-30% 5-year stroke rate if untreated)
• Requires anticoagulation (warfarin, INR 2-3)

4. Pulmonary Hypertension (Common in mitral stenosis)

• Results from chronic elevation of left atrial pressure
• Irreversible if severe and long-standing
• Limits benefits of surgical intervention

5. Infective Endocarditis

• Lifetime risk 0.5-1% per year in RHD patients
• Higher risk with prosthetic valves post-surgery
• Requires antibiotic prophylaxis for dental/invasive procedures

---

8. Prognosis & Outcomes

Natural History Without Treatment

Acute Phase:

• Self-limiting arthritis (resolves in weeks)
• Chorea resolves spontaneously in 3-6 months (though may relapse)
• Carditis: may resolve but often progresses to chronic valve disease

Long-Term:

• Recurrence rate: ~50% within 5 years without prophylaxis [8]
• RHD development: 30-50% of patients with carditis develop chronic RHD [4]
• Mortality: Primarily from heart failure in RHD (10-year survival ~60% if severe RHD untreated)

Outcomes with Treatment

Prognostic Factors

Good Prognosis Indicators:

• No carditis or mild carditis at presentation
• Prompt diagnosis and treatment
• Adherence to secondary prophylaxis [5]
• No recurrences
• Access to cardiac care if RHD develops
• Low-risk geography (sporadic ARF settings)

Poor Prognosis Indicators:

• Severe carditis at presentation (heart failure, pancarditis)
• Recurrent ARF episodes (cumulative valve damage) [8]
• Non-adherence to prophylaxis
• Delayed diagnosis (> 4 weeks from symptom onset)
• High-risk geography (endemic settings with limited healthcare access)
• Development of atrial fibrillation or pulmonary hypertension (indicates advanced RHD)

Specific Outcomes by Manifestation

Arthritis:

• Resolution: 100% without joint deformity
• Recurrence: Only with ARF recurrence
• Timeframe: 2-4 weeks (faster with aspirin)

Chorea:

• Resolution: 90% by 6 months, 95% by 12 months [6]
• Relapse rate: ~20%, can occur years later
• Long-term: Rarely, mild movement abnormalities persist; behavioral/psychiatric sequelae in subset

Carditis/RHD:

• Mild carditis: 70% chance of complete resolution if no recurrence and adherent to prophylaxis [4]
• Moderate-severe carditis: 30-50% develop chronic RHD [4]
• RHD progression: Variable, depends on initial severity, recurrences, genetic factors
• Surgery requirement: ~20-30% of RHD patients eventually require valve intervention [16]

Survival by Valve Disease Severity (Untreated RHD):

• Mild RHD: 10-year survival ~90%
• Moderate RHD: 10-year survival ~75%
• Severe RHD: 10-year survival ~60%
• Post-valve surgery: 10-year survival 85-90% [16]

Impact of Secondary Prophylaxis

Landmark Evidence: [5]

• Reduces ARF recurrence from ~50% to less than 5% over 5 years
• Prevents RHD in ~50% of patients who would have developed it
• Most cost-effective intervention in ARF management (estimated $200-500 per DALY averted in endemic settings) [17]

Adherence Challenges:

• Global adherence rates: ~50-60% with IM benzathine penicillin, ~30-40% with oral regimens
• Major barriers: Injection pain, access (distance to clinics, stock-outs), lack of patient registries
• Solutions: SMS reminders, community health workers, school-based programs improve adherence to 70-85% [17]

---

9. Evidence & Guidelines

Key Guidelines

1. AHA 2015 Scientific Statement - Revised Jones Criteria [2]

Citation: Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131(20):1806-1818. doi: 10.1161/CIR.0000000000000205

Key Recommendations:

• Differentiate diagnostic criteria by population ARF risk (low vs moderate-high-risk)
• Include subclinical (echocardiographic) carditis as major criterion
• Monoarthritis/monoarthralgia elevated to major/minor criteria in moderate-high-risk populations
• Lower inflammatory marker thresholds in endemic settings
• Strength: Class I (strong recommendation, evidence level A)

2. AHA 2020 Scientific Statement - Contemporary RHD Management [16]

Citation: Kumar RK, Antunes MJ, Beaton A, et al. Contemporary Diagnosis and Management of Rheumatic Heart Disease: Implications for Closing the Gap: A Scientific Statement From the American Heart Association. Circulation. 2020;142(20):e337-e357. doi: 10.1161/CIR.0000000000000921

Key Recommendations:

• Secondary prophylaxis duration: lifelong consideration for all RHD patients in endemic settings
• Echocardiographic screening using WHF criteria can identify subclinical RHD [11]
• Multidisciplinary team approach for RHD management
• Patient registries essential for prophylaxis adherence [17]
• Strength: Class I recommendation for prophylaxis, Class IIa for echocardiographic screening

3. WHO 2004 - Rheumatic Fever and RHD Expert Consultation

Citation: World Health Organization. Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation. WHO Technical Report Series 2004;923:1-122.

Key Recommendations:

• Jones criteria application in developing countries
• Emphasis on primary prevention through improved GAS pharyngitis treatment
• Secondary prophylaxis protocols
• Limitation: Predates 2015 Jones revision; historically important

4. Cochrane Systematic Reviews

A. Anti-Inflammatory Treatment [14]

Citation: Cilliers A, Adler AJ, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev. 2015;(5):CD003176. doi: 10.1002/14651858.CD003176.pub3

Findings:

• No evidence that corticosteroids or aspirin prevent long-term RHD (1-year outcomes)
• Corticosteroids may hasten acute carditis symptom resolution
• No significant difference in outcomes between steroids vs aspirin in most trials
• Quality of evidence: Low-moderate (old trials, substantial bias risk)

B. Secondary Prophylaxis [5]

Citation: Bray JJ, Thompson S, Seitler S, et al. Long-term antibiotic prophylaxis for prevention of rheumatic fever recurrence and progression to rheumatic heart disease. Cochrane Database Syst Rev. 2024;9(9):CD015779. doi: 10.1002/14651858.CD015779

Findings:

• Benzathine penicillin G reduces recurrence vs no treatment (RR 0.39, 95% CI 0.22-0.69)
• IM regimens superior to oral for adherence
• Optimal duration: evidence supports minimum 10 years for patients with carditis
• Quality of evidence: Moderate-high

Landmark Trials & Studies

1. Pediatrics in Review 2021 - Contemporary ARF Epidemiology [1]

Citation: Lahiri S, Sanyahumbi A. Acute Rheumatic Fever. Pediatr Rev. 2021;42(5):221-232. doi: 10.1542/pir.2019-0288

Key Findings:

• Global incidence 8-51 per 100,000
• Timely GAS treatment prevents ARF; benzathine penicillin prophylaxis prevents recurrence
• RHD research underfunded; need for public health advocacy

2. Consensus Guidelines - Sydenham Chorea 2025 [6]

Citation: Thomas T, Eyre M, Ferrarin E, et al. Evaluation, Diagnosis, and Treatment of Sydenham Chorea: Consensus Guidelines. Pediatrics. 2025;156(6):e2025072466. doi: 10.1542/peds.2025-072466

Key Findings:

• International Delphi consensus (27 experts)
• Corticosteroids recommended in moderate-severe SC
• IVIG or plasma exchange for inadequate responders
• Screen for carditis and other ARF features
• Long-term secondary prophylaxis per local guidelines

3. ASO and Anti-DNase B Testing [10]

Citation: Steer AC, Vidmar S, Ritika R, et al. Normal ranges of streptococcal antibody titers are similar whether streptococci are endemic to the setting or not. Clin Vaccine Immunol. 2009;16(2):172-175. doi: 10.1128/CVI.00291-08

Key Findings:

• Combined ASO + anti-DNase B achieves ~95% sensitivity for recent GAS infection
• Anti-DNase B more sensitive than ASO for pharyngeal infections
• Upper limit of normal similar across populations (ASO > 200-320 IU/mL, anti-DNase B > 240 Todd units)

4. Pulse Steroid Therapy - Severe Carditis [15]

Citation: Torres RPA, Torres RFA, Torres RA, Torres RSLA. Pulse therapy combined with oral corticosteroids in the management of severe rheumatic carditis and rebound. Cardiol Young. 2018;28(2):309-314. doi: 10.1017/S1047951117002062

Key Findings:

• 120 patients with severe carditis treated with methylprednisolone pulse therapy (3 cycles) + oral prednisolone
• Effective in controlling severe inflammation and preventing rebound
• Suggests benefit for severe/refractory cases (case series, moderate evidence)

5. Global RHD Burden [7]

Citation: Watkins DA, Johnson CO, Colquhoun SM, et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. N Engl J Med. 2017;377(8):713-722. doi: 10.1056/NEJMoa1603693

Key Findings:

• 33.4 million people living with RHD globally
• 319,400 deaths annually (10% of global cardiovascular disease burden in developing countries)
• Greatest burden in South Asia, sub-Saharan Africa, Oceania

Evidence Strength Summary

---

10. Patient/Layperson Explanation

What is Acute Rheumatic Fever?

Acute rheumatic fever (ARF) is an inflammatory disease that can develop 2-4 weeks after a strep throat infection, affecting your heart, joints, brain, and skin. It happens when your immune system, while fighting the strep bacteria, mistakenly attacks your own body tissues because parts of the strep bacteria look similar to parts of your heart, joints, and brain. This "molecular mimicry" causes inflammation in multiple organs.

In simple terms: After a strep throat, your immune system can get confused and attack your own body, especially your heart valves, joints, and sometimes your brain. This can cause permanent heart damage if not treated and prevented from happening again.

Who Gets It?

• Age: Mostly children and young adults aged 5-15 years
• Geography: More common in developing countries, Indigenous populations, and areas with overcrowding and limited healthcare access
• After strep throat: Only happens after throat infections with Group A streptococcus (not skin infections)
• Rare in developed countries: Improved living conditions and antibiotic access have made it uncommon in high-income countries, but it still affects millions worldwide

Why Does It Matter?

ARF can cause permanent damage to your heart valves (called rheumatic heart disease or RHD). This valve damage can lead to heart failure, stroke, and death years or decades later if not managed properly. The good news: ARF and RHD are largely preventable with:

1. Prompt treatment of strep throat with antibiotics
2. Long-term penicillin injections if you've had ARF before (this prevents it from happening again)

How is it Diagnosed?

Doctors use the Jones Criteria (updated in 2015), which look for:

Major signs (need 2, or 1 major + 2 minor):

1. Heart inflammation (carditis): New heart murmur, heart failure symptoms
2. Joint pain and swelling (arthritis): Severe pain that "jumps" from one large joint to another (knees, ankles, wrists, elbows)
3. Involuntary movements (chorea): Jerky, dance-like movements, emotional changes (can appear months later)
4. Skin rash (erythema marginatum): Pink rings on trunk/arms (rare)
5. Skin bumps (nodules): Firm painless bumps over elbows/knees (rare)

Minor signs:

• Fever
• Joint pain without swelling
• Blood tests showing inflammation (elevated ESR, CRP)
• ECG showing prolonged PR interval

Plus: Evidence of recent strep infection (throat swab, blood tests for strep antibodies like ASO or anti-DNase B)

Special test: Echocardiogram (ultrasound of the heart) is done in all patients to check for heart involvement, even if there's no murmur. This "subclinical carditis" is now recognized as a major criterion.

How is it Treated?

1. Treat the Strep Infection (Immediately)

• Penicillin injection (one large dose in the muscle), OR
• Penicillin pills for 10 days
• Why: Kill any remaining strep bacteria
• If allergic: Alternative antibiotics like azithromycin

2. Reduce Inflammation

• Aspirin (high dose) if no heart involvement or mild cases
  • "Dose: 100 mg per kg per day (maximum 4-6 grams/day) for 4-6 weeks, then taper"
  • Very effective for joint pain (relief within 24-48 hours)
• Steroids (prednisolone) if heart inflammation present
  • "Dose: 1-2 mg per kg per day for 2-4 weeks, then taper"
  • Severe carditis: May use IV methylprednisolone "pulse" therapy (3 days of high-dose IV steroids)
• Why: Reduce inflammation, relieve symptoms, possibly limit heart damage
• Evidence: Cochrane review shows these treatments help acute symptoms but haven't been proven to prevent long-term heart valve damage

3. Supportive Care

• Bed rest: Especially important if heart is involved (reduces heart strain)
• Heart failure treatment: If severe carditis causes fluid buildup (diuretics, ACE inhibitors, oxygen)
• Chorea treatment: If involuntary movements are severe (medications like haloperidol or valproate, or steroids/IVIG)

4. Long-Term Prevention (MOST IMPORTANT) - Secondary Prophylaxis

This is the most critical part of treatment. Once you've had ARF, you need regular penicillin to prevent it from happening again.

Regimen:

• Preferred: Penicillin injection (benzathine penicillin G, 1.2 million units) in the muscle every 3-4 weeks
• Alternative: Penicillin pills (250 mg) twice daily, every day
• If allergic: Sulfadiazine or erythromycin pills daily

Duration:

• No heart involvement: Until age 21 OR 5 years after ARF (whichever is longer)
• Had heart involvement but no permanent damage: Until age 21 OR 10 years after ARF (whichever is longer)
• Permanent heart valve damage (RHD): Until age 40 OR lifelong (depending on severity and risk)

Why this matters:

• Without these injections: ~50% chance ARF comes back within 5 years
• With regular injections: less than 5% chance of recurrence
• Each time ARF returns, it causes more heart valve damage
• Adherence is challenging: Injections are painful; many people miss doses. Using reminders (SMS), community health workers, and patient support groups can help.

What to Expect

Acute Phase (First 6-12 Weeks):

• Arthritis: Improves dramatically within 24-48 hours of starting aspirin; completely resolves in 2-4 weeks
• Carditis: Inflammation gradually improves over weeks to months with treatment
• Chorea: May persist 3-6 months (sometimes longer); movements eventually stop in 90% by 6 months

Long-Term:

• If no heart involvement: Complete recovery expected; low risk if prophylaxis maintained
• If heart involvement: 30-50% chance of developing permanent valve damage (RHD) even with treatment
  • RHD symptoms may not appear for years to decades
  • Can cause heart failure, stroke, need for valve surgery
• Chorea: ~20% chance of relapse (can occur years later)

Pregnancy Considerations: Women with RHD need specialist care during pregnancy (high-risk obstetrics, cardiology input)

When to Seek Help

See your doctor immediately if:

• Recent strep throat followed by severe joint pain, fever, breathlessness, or skin rash
• Known history of ARF with new symptoms (possible recurrence)
• Experiencing involuntary movements or behavioral changes after strep throat

Call emergency services (999/911) if:

• Severe breathlessness, can't lie flat
• Chest pain with breathlessness
• Fainting or feeling like you're going to faint
• Severe chorea with inability to swallow (aspiration risk)

Living with ARF History / RHD

If you've had ARF before:

1. NEVER miss your prophylaxis injections/pills - this is the most important thing
2. Treat any sore throat promptly (see doctor, may need antibiotics)
3. Tell all healthcare providers about your ARF history
4. If you develop RHD:
   • Regular cardiology follow-up (annual echocardiograms)
   • May need antibiotics before dental procedures (endocarditis prevention)
   • Avoid pregnancy without specialist guidance
   • May eventually need valve surgery (repair or replacement)

Key Message: ARF is preventable, and with proper treatment and prophylaxis, you can live a normal, healthy life. The key is adhering to long-term penicillin prevention to protect your heart.

---

11. References

Primary Guidelines & Landmark Papers

1. Lahiri S, Sanyahumbi A. Acute Rheumatic Fever. Pediatr Rev. 2021;42(5):221-232. doi: 10.1542/pir.2019-0288

2. Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131(20):1806-1818. doi: 10.1161/CIR.0000000000000205

3. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee. Circulation. 2009;119(11):1541-1551. doi: 10.1161/CIRCULATIONAHA.109.191959

4. Kumar RK. Controlling rheumatic heart disease in developing countries. World J Cardiol. 2010;2(7):186-187. doi: 10.4330/wjc.v2.i7.186

5. Bray JJ, Thompson S, Seitler S, et al. Long-term antibiotic prophylaxis for prevention of rheumatic fever recurrence and progression to rheumatic heart disease. Cochrane Database Syst Rev. 2024;9(9):CD015779. doi: 10.1002/14651858.CD015779

6. Thomas T, Eyre M, Ferrarin E, et al. Evaluation, Diagnosis, and Treatment of Sydenham Chorea: Consensus Guidelines. Pediatrics. 2025;156(6):e2025072466. doi: 10.1542/peds.2025-072466

7. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. N Engl J Med. 2017;377(8):713-722. doi: 10.1056/NEJMoa1603693

8. Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Primers. 2016;2:15084. doi: 10.1038/nrdp.2015.84

9. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470-511. doi: 10.1128/CMR.13.3.470

10. Steer AC, Vidmar S, Ritika R, et al. Normal ranges of streptococcal antibody titers are similar whether streptococci are endemic to the setting or not. Clin Vaccine Immunol. 2009;16(2):172-175. doi: 10.1128/CVI.00291-08

11. Remenyi B, Wilson N, Steer A, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline. Nat Rev Cardiol. 2012;9(5):297-309. doi: 10.1038/nrcardio.2012.7

12. Cardoso F, Eduardo C, Silva AP, Mota CC. Chorea in fifty consecutive patients with rheumatic fever. Mov Disord. 1997;12(5):701-703. doi: 10.1002/mds.870120512

13. Orsini A, Santangelo A, Costagliola G, et al. Management, treatment, and clinical approach of Sydenham's chorea in children: Italian survey on expert-based experience. Eur J Paediatr Neurol. 2024;52:103-108. doi: 10.1016/j.ejpn.2024.08.002

14. Cilliers A, Adler AJ, Saloojee H. Anti-inflammatory treatment for carditis in acute rheumatic fever. Cochrane Database Syst Rev. 2015;(5):CD003176. doi: 10.1002/14651858.CD003176.pub3

15. Torres RPA, Torres RFA, Torres RA, Torres RSLA. Pulse therapy combined with oral corticosteroids in the management of severe rheumatic carditis and rebound. Cardiol Young. 2018;28(2):309-314. doi: 10.1017/S1047951117002062

16. Kumar RK, Antunes MJ, Beaton A, et al. Contemporary Diagnosis and Management of Rheumatic Heart Disease: Implications for Closing the Gap: A Scientific Statement From the American Heart Association. Circulation. 2020;142(20):e337-e357. doi: 10.1161/CIR.0000000000000921

17. Zühlke L, Mirabel M, Marijon E. Congenital heart disease and rheumatic heart disease in Africa: recent advances and current priorities. Heart. 2013;99(21):1554-1561. doi: 10.1136/heartjnl-2013-303896

18. Sliwa K, Johnson MR, Zilla P, Roos-Hesselink JW. Management of valvular disease in pregnancy: a global perspective. Eur Heart J. 2015;36(18):1078-1089. doi: 10.1093/eurheartj/ehv050

Additional Key References

19. Beaton A, Carapetis J. The 2015 revision of the Jones criteria for the diagnosis of acute rheumatic fever: implications for practice in low-income and middle-income countries. Heart Asia. 2015;7(2):7-11. doi: 10.1136/heartasia-2015-010648

20. Zühlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J. 2015;36(18):1115-1122. doi: 10.1093/eurheartj/ehu449

21. Wilson N. Secondary prophylaxis for rheumatic fever: simple concepts, difficult delivery. World J Pediatr Congenit Heart Surg. 2013;4(4):380-384. doi: 10.1177/2150135113497240

22. Alberio AMQ, Biagini Y, Di Gangi A, et al. Revising the value of Antistreptolysin O titre in childhood and its interpretation in the diagnostic approach of rheumatic diseases. Eur J Pediatr. 2024;183(2):835-842. doi: 10.1007/s00431-023-05269-6

Further Resources

• WHO Guidelines: World Health Organization. Rheumatic fever and rheumatic heart disease. WHO Technical Report Series 2004;923. https://www.who.int
• AHA Guidelines: American Heart Association scientific statements on ARF/RHD. https://www.heart.org
• RHD Action: Global advocacy and resource hub. https://www.rhdaction.org
• WHF RHD: World Heart Federation rheumatic heart disease resources. https://world-heart-federation.org

---

Last Reviewed: 2026-01-10 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with appropriate specialists. This information is not a substitute for professional medical advice, diagnosis, or treatment. Always verify current guidelines and evidence as clinical practice evolves.